Joël EYER, PhD
Chairman of the Board
Joël Eyer, Research Director at INSERM 1066 / CNRS 6021 "Micro and Nano Translational Medicines" (MINT) in Angers, was the director of the "Laboratory of Neurobiology and Transgenesis" UPRES EA 3143 of Angers Universty from 2000 to 2016.
With nearly 25 years of experience in the field of neuroscience research, Joel Eyer is an internationally recognized expert on the neuronal cytoskeleton, particularly neurofilaments. He is the principal discoverer of the NFL-TBS.40-63 technology (GlioVector and GC01), and co-inventor of the three patents protecting its various applications.
Joël Eyer also has extensive experience in the development of animal models, particularly murine, and he has chaired the Ethics Committee on Animal Experimentation in Pays-de-la-Loire since 2004.
Joël Eyer has been a scientific expert at the European Commission since 2005 and Chair-Person for the evaluation of the Marie Sk?odowska-Curie actions since 2013.
Prof. Marc-Eric HALATSCH
Prof. Marc-Eric Halatsch is Chief Consultant Neurosurgeon at Cantonal Hospital of Winterthur, Switzerland. Previously, he was Vice-President of the Department of Neurosurgery of the Medical School of Ulm University in Germany and from 2005 to 2009, he was an associate professor of neurosurgery and resident of neurosurgery at Heidelberg University Medical School.
His areas of clinical interest and research are neuro-oncology, including glioblastoma, intraoperative imaging, pediatric neurosurgery, EGF receptor and targeted therapy. He has authored more than 70 scientific papers in international publications and is a member of the Reading Committee of several scientific and medical journals.
Prof. Marc-Eric Halatsch is a medical graduate and doctor of science from the medical school of the University of Göttingen.
Dr. Jean-Pierre BIZZARI
Jean-Pierre Bizzari, M.D., is a world-renowned oncology expert. He is a member of the Scientific Advisory Board of the French National Cancer Institute (INCa), member of the International Board of MATWIN (UNICANCER group) and Chairman of the New Drug Advisory Committee of the European Organization of Research and Treatment of Cancer (EORTC).
Previously, Dr. Bizzari was in charge of the clinical development in oncology of several major international pharmaceutical groups. He notably served as Executive Vice-President, and Director of Clinical Oncology (U.S., Europe, and Asia/Japan) at Celgene from 2008 to 2015. He has been involved in the clinical development of several anticancer agents such as Taxotere®, Eloxatin®, Abraxane®, Irinotecan® and also Gliadel® wafer for the treatment of glioblastoma.
Dr. Bizzari has published more than 70 articles in peer-reviewed journals and more than 160 abstracts in scientific congresses, notably on clinical trial methodology and pharmacokinetic/pharmcodynamic studies.
Jean-Pierre Bizzari holds a medical degree specialized in oncology from the University of Nice (France) and has trained successively at the Pitié-Salpêtrière hospital in Paris, at the Ontario Cancer Institute, and then the Montreal McGill Cancer Center in Canada.
Dr. Joël Richard, PhD, HDR
Dr. Joël Richard, an expert in physico-chemistry and biopharmaceutical R&D, is Head of Technical and Pharmaceutical Operations at MedinCell.
Previously, Joël Richard was Senior Vice President of Peptide Development at Ipsen, in charge of supervising all pharmaceutical development and clinical batch production activities for the pharmaceutical group's peptides and small molecules worldwide. Dr Joël Richard was also Chief Executive Officer of OctreoPharm Sciences GmbH, a subsidiary of the Ipsen group specialising in radiopharmaceuticals for the diagnosis and treatment of cancer. Prior to that, Joël Richard was Director of Pharmaceutical Development of Biological Molecules for the Serono and Merck Serono groups, and also Vice President Research and Director of R&D Europe for Ethypharm.
Dr. Joël Richard has focused his research activities on new formulations and drug delivery systems, such as microspheres, nanoparticles, polymers, chemically modified proteins and supercritical fluid technology, in particular for injectable protein and peptide preparations. He has published 68 peer-reviewed scientific articles, 8 book chapters and is the author of more than 130 international papers and 53 patent families.
Joël Richard is a graduate of the Ecole Normale Supérieure de Cachan (Paris, FR). He obtained his PhD in colloid and interface science at the Pierre and Marie Curie University Paris VI and his Habilitation to Direct Chemistry Research at the University of Bordeaux I.